Recursion Pharmaceuticals (NASDAQ:RXRX) Sees Unusually-High Trading Volume – Should You Buy?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) shares saw unusually-strong trading volume on Monday . Approximately 4,632,423 shares traded hands during trading, a decline of 29% from the previous session’s volume of 6,480,514 shares.The stock last traded at $7.78 and had previously closed at $6.95.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on RXRX shares. Leerink Partners reduced their price target on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a research report on Tuesday, September 3rd. Needham & Company LLC reiterated a “buy” rating and set a $11.00 target price on shares of Recursion Pharmaceuticals in a research report on Wednesday, December 11th. Finally, Jefferies Financial Group dropped their price target on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating for the company in a research report on Tuesday, September 3rd. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $9.25.

Recursion Pharmaceuticals Stock Performance

The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. The stock’s 50 day moving average price is $6.73 and its two-hundred day moving average price is $7.25. The firm has a market capitalization of $2.18 billion, a PE ratio of -4.85 and a beta of 0.85.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The business had revenue of $26.08 million for the quarter, compared to analysts’ expectations of $12.62 million. During the same period last year, the business earned ($0.43) earnings per share. The company’s revenue for the quarter was up 147.6% on a year-over-year basis. On average, equities analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Insiders Place Their Bets

In other news, CEO Christopher Gibson sold 20,000 shares of the business’s stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $6.16, for a total transaction of $123,200.00. Following the completion of the sale, the chief executive officer now directly owns 762,656 shares of the company’s stock, valued at $4,697,960.96. The trade was a 2.56 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Michael Secora sold 15,000 shares of Recursion Pharmaceuticals stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $7.66, for a total transaction of $114,900.00. Following the transaction, the chief financial officer now owns 1,499,631 shares in the company, valued at $11,487,173.46. The trade was a 0.99 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 119,235 shares of company stock valued at $802,988. Company insiders own 15.75% of the company’s stock.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in RXRX. Allspring Global Investments Holdings LLC acquired a new position in Recursion Pharmaceuticals in the 3rd quarter worth $25,000. Farther Finance Advisors LLC lifted its holdings in Recursion Pharmaceuticals by 176.9% in the 3rd quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company’s stock worth $42,000 after buying an additional 4,091 shares in the last quarter. Amalgamated Bank lifted its holdings in Recursion Pharmaceuticals by 52.4% in the 2nd quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock worth $54,000 after buying an additional 2,459 shares in the last quarter. KBC Group NV increased its position in shares of Recursion Pharmaceuticals by 79.9% in the 3rd quarter. KBC Group NV now owns 7,602 shares of the company’s stock worth $50,000 after purchasing an additional 3,377 shares during the last quarter. Finally, San Luis Wealth Advisors LLC bought a new stake in shares of Recursion Pharmaceuticals in the 3rd quarter worth about $69,000. Institutional investors and hedge funds own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.